Genetic alterations in ovarian cancer

A method of determining an estimated outcome or predicting a clinical response to chemotherapy for a patient having ovarian serous cystadenocarcinoma (OV), comprising;

• detecting, in a biological sample from a patient having OV, indicators of differential copy numbers, between cancer cells and normal cells, of at least one of (a) at least two nucleic acid sequences selected from the group consisting of SEQ ID NO:
• 1, SEQ ID NO:
• 7, SEQ ID NO:
• 21, SEQ ID NO:
• 25, SEQ ID NO:
• 27, SEQ ID NO:
• 29, SEQ ID NO:
• 31, SEQ ID NO:
• 41, SEQ ID NO:
• 47, SEQ ID NO:
• 56, SEQ ID NO:
• 64, SEQ ID NO:
• 70, SEQ ID NO:
• 81, SEQ ID NO:
• 96;
• (b) amino acid sequences encoded by the nucleic acid sequences of (a);
• or (c) sequences of at least two microRNAs selected from the group consisting of SEQ ID NO:
• 51, SEQ ID NO:
• 60, SEQ ID NO:
• 61, SEQ ID NO:
• 78, SEQ ID NO:
• 79, and SEQ ID NO:
• 80;
• and
• calculating, by a processor, a weighted sum based on the value of the indicators of differential copy numbers;
• and
• estimating, by the processor and based on the weighted sum, a predicted length of survival of the patient or a predicted clinical response to chemotherapy for the patient.

A method for treating a patient having ovarian serous cystadenocarcinoma (OV), comprising:

• administering, in a patient having OV, a treatment based on a predicted length of survival or a predicted clinical response to chemotherapy, wherein the predicted length of survival or the predicted response to chemotherapy is determined by:
• (1) detecting, in a biological sample from a patient having OV, indicators of differential expression, between cancer cells and normal cells, of at least one of (a) at least two nucleic acid sequences selected from the group consisting of SEQ ID NO:
• 1, SEQ ID NO:
• 7, SEQ ID NO:
• 21, SEQ ID NO:
• 25, SEQ ID NO:
• 27, SEQ ID NO:
• 29, SEQ ID NO:
• 31, SEQ ID NO:
• 41, SEQ ID NO:
• 47, SEQ ID NO:
• 56, SEQ ID NO:
• 64, SEQ ID NO:
• 70, SEQ ID NO:
• 81, SEQ ID NO:
• 96;
• (b) amino acid sequences encoded by the nucleic acid sequences of (a);
• or (c) at least two microRNA sequences selected from the group consisting of SEQ ID NO:
• 51, SEQ ID NO:
• 60, SEQ ID NO:
• 61, SEQ ID NO:
• 78, SEQ ID NO:
• 79, and SEQ ID NO:
• 80;
• (2) calculating, by a processor, a weighted sum based on the value of the indicators of differential expression;
• and
• (3) estimating, by the processor and based on the weighted sum, a predicted length of survival of the patient or a predicted clinical response to chemotherapy for the patient.